Cost comparison of predictive genetic testing versus conventional clinical screening for familial adenomatous polyposis

Gut

Volumn 44, Issue 5, 1999, Pages 698-703

  Bapat, B ^a,b   Noorani, H ^a   Cohen, Z ^a   Berk, T ^a   Mitri, A ^a   Gallie, B ^c   Pritzker, K ^a   Gallinger, S ^a   Detsky, A S ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Hosp for Sick C E R I of C   (Canada)

Author keywords

Adenomatous polyposis coil gene; Cost analysis; Familial adenomatous polyposis; Genetic testing

Indexed keywords

ADENOMATOUS POLYP; ARTICLE; COST BENEFIT ANALYSIS; DIAGNOSTIC APPROACH ROUTE; GENE MUTATION; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; PREDICTION; PRIORITY JOURNAL; SCREENING TEST;

EID: 0032965795     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.5.698     Document Type: Article

References (31)

1. 1 Bulow S, Burn J, Neale K, et al. The establishment of a polyposis register. Im J Colorectal Dis 1993;8:34-8.
2. 2 Bussey HJR. Familial polyposis coli. Family studies, histopathology, differential diagnosis, and results of treatment. Baltimore: Johns Hopkins University Press, 1975.
3. 3 Morson B. The polyp-cancer sequence in the large bowel. Proc R Soc Med 1974;67:451-7.
4. 4 Berk T, Stern HS. Screening, management, and surveillance for families with familial adenomatous polyposis. Gastrointest Endosc Clin North Am 1993;3:725-36.
5. 5 Bapat BV, Parker JA, Berk T, et al. Combined use of molecular and biomarkers for presymptomatic carrier risk assessment in familial adenomatous polyposis: implications for screening guidelines. Dis Colon Rectum 1994;37:165 71.
6. 6 Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
7. 7 Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253: 661-5.
8. 8 Joslyn G, Carlson M, Thliveris A, et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991;66:601-13.
9. 9 Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9.
10. 10 Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993;2:425-34.
11. 11 Beroud C, Soussi T. APC gene: data base of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 1996;24:121-4.
12. 12 Belchetz LA, Berk T, Bapat B, et al. Changing causes of mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 1996;39:384-7.
13. 13 Sox HC, Blatt MA, Higgins MC, et al. Medical decision making. Stoneham: Butterworths, 1988.
14. 14 Kassirer JP, Moskowitz AJ, Lau J, et al. Decision analysis: a progress report. Ann Intern Med 1987;106:275-91.
15. 15 Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature. VII. How to use a clinical decision analysis. A. Are the results of the study valid? JAMA 1995;273:1292-5.
16. 16 Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? JAMA 1995;273:1610-13.
17. 17 Mandl M, Paffenholz R, Friedl W, et al. Frequency of common and novel inactivating APC mutations in 202 families with familial adenomatous polyposis. Hum Mol Genet 1994;3:181-4.
18. 18 Powell SM, Peterson GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993;329:1982-7.
19. 19 Cleverley WO. Capital Budgeting. In: Cleverley WO, ed. Handbook of health care accounting and finance. 2nd edn. Rockville: Aspen, 1989:285-310.
20. 20 Krahn M, Gafni A. Discounting in the economic evaluation of health care services. Med Care 1993;31:403-18.
21. 21 Schedule of Benefits: physician services under the Health Insurance Act. Ontario Ministry of Health, 1992.
22. 22 Hollenberg JP. SMLTREE, Version 2.9. Roslyn, NY, 1989.
23. 23 Prosser J, Condie A, Wright M, et al. APC mutation analysis by chemical cleavage of mismatch and a protein truncation assay in familial adenomatous polyposis. Br J Cancer 1994; 61:841-6.
24. 24 Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med 1980;302:1109-17.
25. 25 Burt R, Groden J. The genetic and molecular diagnosis of adenomatous polyposis coli. Gastroenterology 1993;104: 1211-14.
26. 26 Petersen GM. Knowledge of the adenomatous polyposis coli gene and its clinical application. Ann Med 1994;26: 205-8.
27. 27 Park J-G, Han H-J, Won Y-J, et al. Familial adenomatous polyposis and hereditary non-polyposis colorectal cancer in Korea. In: Baba S, ed. New strategies for treatment of hereditary colorectal cancer. Tokyo: Churchill Livingstone, 1996: 213-28.
28. 28 Jass JR, Stewart SM. Evolution of hereditary non-polyposis colorectal cancer. Gut 1992;33:783-6.
29. 29 MacDonald F, Morton DG, Rindl PM, et al. Predictive diagnosis of familial adenomatous polyposis with linked DNA markers: a population based study. BMJ 1992;304: 869-72.
30. 30 Burn J, Chapman P, Delhanty JDA, et al. The UK Northern Region genetic register for familial adenomatous polyposis coli: the use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations. J Med Genet 1991;28:289-96.
31. 31 Rhodes M, Bradburn DM. Overview of screening and management of familial adenomatous polyposis. Gut 1992;33: 125-31.